Keith Speights
Contributor at The Motley Fool (U.S.)
Investor, author, and regular contributor to The Motley Fool. Views are solely mine.
Articles
-
3 days ago |
fool.com | Keith Speights |David Jagielski
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years. Some of them didn't even exist that long ago. Others were only a fraction of their current size. What if you could buy potential huge winners of the future while they have relatively small market caps? Three Motley Fool contributors believe you can.
-
5 days ago |
fool.com | Keith Speights
Shares of Iovance Biotherapeutics (IOVA -45.90%) were crashing 46.6% lower as of 10:40 a.m. ET on Friday. The huge decline came after the drugmaker announced its first-quarter results before the market opened. Iovance reported Q1 revenue of $49.3 million, $43.6 million of which came from its advanced melanoma drug, Amtagvi.
-
6 days ago |
fool.com | Keith Speights
Financial services stocks aren't enjoying the kind of year many thought they would so far in 2025. The prospects of lower interest rates and relaxation of regulations by the Trump administration seemed promising. However, those predicting a positive environment for financial services stocks weren't counting on the president's steep tariffs throwing the stock market for a loop.
-
6 days ago |
fool.com | Keith Speights
Like most stocks, Energy Transfer LP (ET 3.08%) has been quite volatile so far in 2025. However, nervous investors received great news from the midstream energy company on Tuesday. Energy Transfer's unit price popped following its first-quarter update. But the Q1 numbers weren't the main story. This 7.8%-yielding stock is poised for accelerating growth. A solid Q1Energy Transfer announced net income for the first quarter of $1.32 billion, or $0.36 per diluted unit.
-
6 days ago |
yahoo.com | Keith Speights
Key PointsAnalysts overwhelmingly recommend buying Ares Capital and think the stock will rise over the next 12 months. Economic uncertainty could present a big opportunity for the business development company. Ares Capital appears to be an income investor's dream stock with its ultra-high dividend yield and solid dividend track record. Financial services stocks aren't enjoying the kind of year many thought they would so far in 2025.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 737
- DMs Open
- No
RT @MotleyFoolMoney: A recession is coming... eventually. @WilyLewis and @asitmap break down what housing data reveals about the big macro…
Thanks, @anandchokkavelu , @ebcapital , and @louwhiteman for coming to my defense. It's a tough crowd in the Twitterverse at times! 🙂
Which pharmacies will compete best against $AMZN now that the e-commerce giant is officially now a rival? I'd go with $CVS and $WMT. But $AMZN will be a formidable competitor.
